[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Reema A. Patel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100477150","phase-2-imatinib-tdm-in-gist-100477150",false,"NCT05493215","Imatinib TDM in GIST","A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal Tumor","Inclusion Criteria:\n\n* Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)\n* Currently receiving imatinib initiated within the last 3 months or to be started in the next 1 month\n* Prior systemic chemotherapy for other malignancy is allowed as long as it was completed within the past 6 months and there is no evidence of disease\n* Age ≥18 years\n* ECOG performance status of 0 or 1\n* Normal organ function\n\nExclusion Criteria:\n\n* Presence of PDGFRA D842V mutation\n* Known allergy to imatinib or allergic reactions to compounds of similar chemical or biologic composition to the study drug\n* Concomitant anticoagulation with oral warfarin.\n* Use of strong inhibitors or inducers of CYP3A or CYP3A4, drugs metabolized by CYP3A4 or CYP2D6\n* Uncontrolled intercurrent illness\n* Concurrent malignancy","ALL","18 Years",{"count":19,"type":20},28,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.",[26],"Gastrointestinal Stromal Tumors","RECRUITING","2026-02-11",{"date":30,"type":31},"2026-02-17","ACTUAL",{"date":33,"type":31},"2024-03-26",{"date":35,"type":20},"2027-12",{"name":37,"class":38},"Reema A. Patel","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100469309","genocare-a-prospective-randomized-clinical-trial-of-genotype-guided-dosing-versus-usual-care-100469309","NCT05391126","GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care","Inclusion Criteria:\n\n* Patients must have histologically confirmed stage I-IV pancreas or stage III-IV colorectal cancer who are planning to undergo treatment.\n* Prior treatment is allowed, specifically surgery and\u002For radiation and non-irinotecan containing regimens are allowed.\n* Age ≥ 18 years.\n* ECOG performance status ≤ 1.\n* Patients must have adequate organ and marrow function as defined below:\n* Measurable or non-measurable disease.\n\nExclusion Criteria:\n\n* Patients who received prior treatment with irinotecan are excluded.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with targeted therapy, in the opinion of the treating physician.\n* Pregnant women are excluded from this study.\n* Patients who are not planned for treatment of their cancer.",{"count":47,"type":20},178,[49],"NA","This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\\*1\u002F\\*28) (heterozygotes) and usual UGT metabolizers (\\*1\u002F\\*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (\\*1\u002F\\*28, \\*1\u002F\\*1) will be randomized to genotype-guided dosing versus usual care.",[52,53],"Colorectal Cancer","Pancreatic Cancer","2025-12-08",{"date":56,"type":31},"2025-12-16",{"date":58,"type":31},"2022-09-28",{"date":60,"type":20},"2027-05",{"name":37,"class":38},""]